Senators question Allergan CEO on tribe patent deal

A group of five senators said the deal was a "blatant attempt to further Allergan's market monopoly" on its $1.5 billion eye drug, Restasis.

Allergan Gains Another Approval for Botox Amid Patent Controversy Over Restasis - Xtalks

Allergan deal with Mohawk tribe casts patent shadow

CONTROVERSIAL STRATEGY: SELLING PATENTS TO A NATIVE AMERICAN TRIBE

Does Allergan's Saint Regis Mohawk Tribe transactional move rip off consumers? - The IPKat

Allergan's Restasis to Face Impending Generic Competition After Patent License Play Fails - Xtalks

Irish America August / September 2019 by Irish America Magazine - Issuu

Goldman Sachs Asks: 'Is Curing Patients A Sustainable Business Model?' - Above the Law

Allergan deal with Mohawk tribe casts patent shadow

Page 67 – Business North Carolina

Allergan Patent Deal May Hurt Competition, Lawmakers Say - Bloomberg

Allergan Gains Another Approval for Botox Amid Patent Controversy Over Restasis - Xtalks